Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male subject~2. Subject voluntarily agrees to participate in this study~Exclusion Criteria:~1. Female.~2. Subject has a medical condition of disease including one or more.~3. Smoker

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- CT-P6 (Type: ACTIVE_COMPARATOR): Trastuzumab
- US-licensed Herceptin (Type: ACTIVE_COMPARATOR): Trastuzumab

Based on this trial design, predict the completion outcome and termination type (if applicable).